TY - JOUR
T1 - Predicting outcome after traumatic brain injury
T2 - Practical prognostic models based on large cohort of international patients
AU - MRC CRASH Trial Collaborators
AU - Perel, P. A.
AU - Olldashi, Fatos
AU - Muzha, Itan
AU - Filipi, Nikolin
AU - Lede, Roberto
AU - Copertari, Pablo
AU - Traverso, Carolina
AU - Copertari, Alejandro
AU - Vergara, Enrique Alfredo
AU - Montenegro, Carolina
AU - De Huidobro, Roberto Ruiz
AU - Saladino, Pantaleón
AU - Surt, Karina
AU - Cialzeta, José
AU - Lazzeri, Silvio
AU - Piñero, Gustavo
AU - Ciccioli, Fabiana
AU - Videtta, Walter
AU - Barboza, María Fernanda
AU - Svampa, Silvana
AU - Sciuto, Victor
AU - Domeniconi, Gustavo
AU - Bustamante, Marcelo
AU - Waschbusch, Maximiliano
AU - Gullo, María Paula
AU - Drago, Daniel Alberto
AU - Linares, Juan Carlos Arjona
AU - Camputaro, Luis
AU - Tróccoli, Gustavo
AU - Galimberti, Hernán
AU - Tallott, Mandy
AU - Eybner, Christian
AU - Buchinger, Walter
AU - Fitzal, Sylvia
AU - Mazairac, Guy
AU - Oleffe, Véronique
AU - Grollinger, Thierry
AU - Delvaux, Philippe
AU - Carlier, Laurent
AU - Braet, Veronique
AU - Jacques, Jean Marie
AU - De Knoop, Danielle
AU - Nasi, Luiz
AU - Choi, Humberto Kukhuyn
AU - Schmitt, Mara
AU - Gentil, André
AU - Nacul, Flavio
AU - Barrios, Pedro Bedoya
AU - Xinkang, Chen
AU - Jooma, Rashid
N1 - Funding Information:
GM receives research funding from Astellas Inc and SymBio Pharmaceuticals Limited. MH receives research funding from Incyte. AS is the site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (clinicaltrials gov. Identifier: NCT03745287) and Novartis (clinicaltrials gov. Identifier: NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to AS institution. AS has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. AS has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. JH receives research funding from Global Blood Therapeutics and consultancy fees from Global Blood Therapeutics, Forma Therapeutics and bluebird bio. SB receives grant support from the American Society of Hematology.
PY - 2008/2/23
Y1 - 2008/2/23
N2 - Objective: To develop and validate practical prognostic models for death at 14 days and for death or severe disability six months after traumatic brain injury. Design: Multivariable logistic regression to select variables that were independently associated with two patient outcomes. Two models designed: "basic" model (demographic and clinical variables only) and "CT" model (basic model plus results of computed tomography). The models were subsequently developed for high and low-middle income countries separately. Setting: Medical Research Council (MRC) CRASH Trial. Subjects: 10 008 patients with traumatic brain injury. Models externally validated in a cohort of 8509. Results: The basic model included four predictors: age, Glasgow coma scale, pupil reactivity, and the presence of major extracranial injury. The CT model also included the presence of petechial haemorrhages, obliteration of the third ventricle or basal cisterns, subarachnoid bleeding, midline shift, and non-evacuated haematoma. In the derivation sample the models showed excellent discrimination (C statistic above 0.80). The models showed good calibration graphically. The Hosmer-Lemeshow test also indicated good calibration, except for the CT model in low-middle income countries. External validation for unfavourable outcome at six months in high income countries showed that basic and CT models had good discrimination (C statistic 0.77 for both models) but poorer calibration. Conclusion: Simple prognostic models can be used to obtain valid predictions of relevant outcomes in patients with traumatic brain injury.
AB - Objective: To develop and validate practical prognostic models for death at 14 days and for death or severe disability six months after traumatic brain injury. Design: Multivariable logistic regression to select variables that were independently associated with two patient outcomes. Two models designed: "basic" model (demographic and clinical variables only) and "CT" model (basic model plus results of computed tomography). The models were subsequently developed for high and low-middle income countries separately. Setting: Medical Research Council (MRC) CRASH Trial. Subjects: 10 008 patients with traumatic brain injury. Models externally validated in a cohort of 8509. Results: The basic model included four predictors: age, Glasgow coma scale, pupil reactivity, and the presence of major extracranial injury. The CT model also included the presence of petechial haemorrhages, obliteration of the third ventricle or basal cisterns, subarachnoid bleeding, midline shift, and non-evacuated haematoma. In the derivation sample the models showed excellent discrimination (C statistic above 0.80). The models showed good calibration graphically. The Hosmer-Lemeshow test also indicated good calibration, except for the CT model in low-middle income countries. External validation for unfavourable outcome at six months in high income countries showed that basic and CT models had good discrimination (C statistic 0.77 for both models) but poorer calibration. Conclusion: Simple prognostic models can be used to obtain valid predictions of relevant outcomes in patients with traumatic brain injury.
UR - http://www.scopus.com/inward/record.url?scp=39749151654&partnerID=8YFLogxK
U2 - 10.1136/bmj.39461.643438.25
DO - 10.1136/bmj.39461.643438.25
M3 - Article
C2 - 18270239
AN - SCOPUS:39749151654
SN - 0959-8146
VL - 336
SP - 425
EP - 429
JO - The BMJ
JF - The BMJ
IS - 7641
ER -